CHICAGO , July 19,
2024 /PRNewswire/ -- The global immunotherapy drugs
market is expected to grow from USD 285.3
billion in 2024 to USD 580.6
billion by 2029, at a CAGR of 15.3% This growth is fuelled
by advancements in antibody engineering, increasing demand for
antibody therapies in cancer treatment, and a rising preference for
personalized and targeted medicines. Immunotherapy drugs work by
enhancing or modulating the immune system to effectively target and
eliminate disease-causing agents. Despite these promising
prospects, the market faces challenges such as the complex and
costly development of antibody therapeutics and stringent
regulatory approval processes. Opportunities include increased
collaborations among pharmaceutical companies, CROs, and academic
institutions, which drive innovation and expedite drug development.
Key segments include antibody drugs and cancer treatments, with
intravenous administration being the fastest-growing route.
North America is expected to
dominate the market, supported by extensive research, high cancer
prevalence, and growing adoption of immunotherapy. Key players in
the market include Merck & Co., Inc., Johnson & Johnson
Services, Inc., F. Hoffman-La Roche Ltd., Pfizer Inc., AstraZeneca,
Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bristol-Myers
Squibb Company, Eli Lilly and Company, Sanofi, Takeda
Pharmaceutical Company Limited, Teva Pharmaceutical Industries
Ltd., GSK PLC, and Abbvie Inc.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755
Browse in-depth TOC on "Immunotherapy Drugs
Market"
341 - Tables
53 - Figures
348 -
Pages
MERCK & CO., INC. (US): Innovator in
Immunotherapy
Merck & Co., Inc. stands out as a leader in the
immunotherapy sector, showcasing a robust pipeline of advanced
immunotherapeutic drugs through the utilization of cutting-edge
biotechnologies. The company's expertise spans therapeutic areas
including oncology, immunology, and infectious diseases, supported
by a strong commitment to research excellence and strategic
collaborations. Merck's focus on immunotherapy is evident in its
targeted acquisitions and partnerships, such as those with
AstraZeneca plc (UK) and Eisai Co., Ltd. (Japan) for cancer immunotherapy. Notable
innovations include KEYTRUDA, a groundbreaking drug for cancer
treatment, highlighting Merck's dedication to developing impactful
therapies and advancing therapeutic innovation.
JOHNSON & JOHNSON SERVICES, INC. (US): Comprehensive
Immunotherapy Solutions
Johnson & Johnson Services, Inc. is a prominent player in
the immunotherapy drugs market, offering a diverse portfolio of
approved therapies across multiple therapeutic areas, including
oncology, immunology, and infectious diseases. The company's
extensive geographical presence and well-established global
distribution network are key strengths, enabling it to address a
wide range of medical needs effectively. Johnson & Johnson's
strategy emphasizes a diversified immunotherapy portfolio, rigorous
quality standards, and strategic partnerships to enhance research
and market access. This approach reduces reliance on any single
drug and supports the development of innovative therapies to meet
diverse patient needs.
F. HOFFMANN-LA ROCHE LTD. (Switzerland): Pioneer in Immunotherapy
Innovations
F. Hoffmann-La Roche Ltd is a leading force in the immunotherapy
drugs market, providing an extensive range of products for
hospitals and specialty care centers. The company boasts several
approved immunotherapy drugs and a strong global distribution
presence. Roche's strengths include pioneering innovative
therapies, rigorous quality control, and deep disease biology
insights, which contribute to developing transformative treatments
and improving patient outcomes. Noteworthy recent developments
include the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal
Primary Antibody and the ATRX Rabbit Polyclonal Antibody in
February 2023, designed to identify
mutation statuses in brain cancer patients.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=137717755
Type Segmentation: Antibody Drugs Dominate
The immunotherapy drugs market is segmented into antibody drugs,
inhibitor drugs, interferons & interleukins, cancer vaccines,
and other immunotherapy drugs, including oncolytic virus therapy
and T-cell therapy. In 2023, antibody drugs held the largest market
share, driven by rising cancer rates, increased adoption of
biological therapies, growing R&D investments, and supportive
government policies. This segment's dominance is expected to
continue, bolstered by ongoing advancements in therapeutic
development and increased focus on personalized medicine.
Application Segmentation: Cancer Leads the Market
The immunotherapy drugs market is categorized by applications
into cancer, autoimmune & inflammatory diseases, hematology,
osteology, neurology, and other areas such as ophthalmology,
dermatology, and cardiovascular diseases. In 2023, cancer emerged
as the leading application area, capturing the largest market
share. This is attributed to the growing prevalence of cancer,
increasing R&D spending, and the expanding array of approved
immunotherapy treatments specifically designed to address various
cancer types.
Route of Administration Segmentation: Intravenous Route is
Key
The market is segmented by route of administration into
intravenous, subcutaneous, and other routes (intravitreal and
intramuscular). In 2023, the intravenous route accounted for the
largest market share and is expected to grow at the highest CAGR
during the forecast period. This growth is driven by the
intravenous route's ability to deliver drugs directly into the
bloodstream, ensuring rapid and consistent therapeutic effects,
particularly for conditions like cancer and autoimmune
diseases.
End User Segmentation: Hospitals Lead
Based on end users, the immunotherapy drugs market is divided
into hospitals, long-term care facilities, and other specialty care
centers. In 2023, hospitals commanded the largest share of the
market. Hospitals extensively utilize monoclonal antibodies (mAbs)
for their targeted therapy capabilities, rapid diagnostic
applications, and effectiveness in treating various diseases,
including cancer, autoimmune disorders, and infectious
diseases.
Regional Insights: North America Holds the Largest
Share
The immunotherapy drugs market is segmented into six regions:
North America, Europe, Asia
Pacific, Latin America, the
Middle East, and Africa. In 2023, North America held the largest market share,
followed by Europe and the
Asia Pacific. The growth in
North America is driven by robust
immunotherapy research, an expanding healthcare sector, increasing
cancer prevalence, and the rising approval and adoption of
immunotherapy drugs for treating chronic diseases.
For more information, inquire now! Inquire Now
Related Reports:
Active Pharmaceutical Ingredient Market
Cancer Biomarkers Market
Laboratory Filtration Market
Biosimilars Market
Pharmaceutical Filtration Market
Get access to the latest updates on Immunotherapy Drugs
Companies and Immunotherapy Drugs Market Share
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.com/news-releases/immunotherapy-drugs-market-worth-580-6-billion-by-2029-driven-by-technological-advancements--marketsandmarkets-302201573.html
SOURCE MarketsandMarkets